$0.13
(Market cap
$936 Mln
Revenue (TTM)
$730 Mln
P/E Ratio
13
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
6.9
-
Debt to Equity
0.8
-
Book Value
$18.1
-
EPS
$1.7
-
Face value
--
-
Shares outstanding
42,537,944
10 Years Aggregate
CFO
$617.40 Mln
EBITDA
$469.83 Mln
Net Profit
$336.90 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amphastar P (AMPH)
| -17.8 | 14.8 | 15.2 | -27.8 | -25.4 | 2.7 | 1.2 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Amphastar P (AMPH)
| -27.9 | -39.7 | 120.7 | 20.3 | 15.8 | 4.3 | -3.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amphastar P (AMPH)
|
22.0 | 936.3 | 730.0 | 78.6 | 11.4 | 10.1 | 13 | 1.2 |
| 17.5 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 199.0 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.9 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.1 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 280.5 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 67.7 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 141.4 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Amphastar P (AMPH)
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal... spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. Read more
-
Chairman of the Board, Chief Scientist & COO
Dr. Ziping Luo Ph.D.
-
Chairman of the Board, Chief Scientist & COO
Dr. Ziping Luo Ph.D.
-
Headquarters
Rancho Cucamonga, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Amphastar P (AMPH)
What is the current share price of Amphastar P (AMPH) Today?
The share price of Amphastar P (AMPH) is $22.01 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Amphastar P (AMPH) has given a return of -25.39% in the last 3 years.
What is the current PB & PE ratio of Amphastar P (AMPH)?
The P/E ratio of Amphastar P (AMPH) is 13.02 times as on 28-Aug-2026, a 65 discount to its peers’ median range of 37.31 times.
The P/B ratio of Amphastar P (AMPH) is 1.21 times as on 28-Aug-2026, a 84 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
12.88 |
1.60 |
2024 |
12.12 |
2.64 |
2023 |
23.84 |
5.13 |
2022 |
15.86 |
2.74 |
2021 |
18.77 |
2.62 |
What is the 52 Week High and Low of Amphastar P (AMPH)?
The 52-week high and low of Amphastar P (AMPH) are Rs 31.26 and Rs 16.65 as of 30-Aug-2026.
What is the market cap of Amphastar P (AMPH)?
Amphastar P (AMPH) has a market capitalisation of $ 936 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Amphastar P (AMPH)?
Before investing in Amphastar P (AMPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.